Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06480565 | A Phase 1/2 Trial of ADI-270 in ccRCC | PHASE1 | ACTIVE NOT_RECRUITING | 60 | — | — | Dec 12, 2024 | Jun 1, 2027 | Aug 15, 2025 | 1 | United States |
This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD)
This primary endpoint will be used to determine the MTD/MAD of ADI-270
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ADI-270 is administered at ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-270 |
| Dose Expansion | EXPERIMENTAL | Dose Expansion with ADI-270 at the MTD/MAD to confirm recommended phase 2 dose (Part 2). |
| Name | Type | Description |
|---|---|---|
| ADI-270 | DRUG | Anti-CD70 CAR-T |
| Fludarabine | DRUG | Chemotherapy for Lymphodepeletion |
| Cyclophosphamide | DRUG | Chemotherapy for Lymphodepletion |
Inclusion Criteria: 1. Histologically or cytologically confirmed clear cell RCC 2. Documented evidence of advanced or metastatic diseases. 3. Patients must have been treated with an immune checkpoint inhibitor and a VEGF inhibitor (the VEGF inhibitor must have been administered in the advanced and/...